Liquid biopsy is challenging for the diagnosis of epithelial ovarian cancer (EOC). In this study, we performed the methylation testing of host DNA, namely, OPCML, FODX3 and CDH13, in the peripheral serum to discover the diagnostic and supervision roles of DNA methylation in EOC patients. The study compromises two stages. In the training set, DNA methylation testing is performed in the ovarian tissues from EOC and paired benign ovarian tumor patients. The cut-off values of methylation are produced in this stage. On the meantime, serum DNA methylation testing is also performed to reveal its accordance and accuracy compared with the results of ovarian tissues. In the validation set, serum DNA methylation testing is performed in unselected ovarian tumor patients with definite cut-off values to validate its accuracy based on known histology of ovarian tumors. In training and validation sets, serum DNA methylation is also performed after major surgeries for EOC as to illustrate the changes of methylation testing, therefore, reflection the supervision role of DNA methylation.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
400
Methylation testing of host DNA, namely, OPCML, FODX3 and CDH13, in the peripheral serum
Lei Li
Beijing, Beijing Municipality, China
RECRUITINGCut-off values of targeted DNA methylation in epithelial ovarian cancer
The cut-off values are achieve by paired epithelial ovarian cancer and benign ovarian tumor patients.
Time frame: Two years
Accuracy of serum DNA methylation in epithelial ovarian cancer
The accuracy is supported by sensitivity, specificity, negative predictive value and positive predictive value.
Time frame: Two years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.